Cargando…
Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms
Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis. Hereby, tyrosine kinases might either be dysregulated intrinsically...
Autores principales: | Kutsch, Nadine, Marks, Reinhard, Ratei, Richard, Held, Thomas K, Schmidt-Hieber, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539014/ https://www.ncbi.nlm.nih.gov/pubmed/26327780 http://dx.doi.org/10.4137/BMI.S22434 |
Ejemplares similares
-
How we treat mature B-cell neoplasms (indolent B-cell lymphomas)
por: Lumish, Melissa, et al.
Publicado: (2021) -
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned
por: Pinilla-Ibarz, Javier, et al.
Publicado: (2016) -
Pulmonary hypertension with dasatinib and other tyrosine kinase
inhibitors
por: El-Dabh, Ashraf, et al.
Publicado: (2019) -
Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020) -
How We Manage Patients with Indolent B-Cell Malignancies on Bruton’s Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists
por: Nixon, Shannon, et al.
Publicado: (2023)